

<b>Finance and Performance Assurance Committee Key Issues Report</b>		
<b>Report Date:</b> 1 February 2022		<b>Report of:</b> Finance and Performance Assurance Committee
<b>Date of last meeting:</b> 1 February 2022		<b>Membership Numbers:</b> The meeting was quorate.
1	<b>Agenda</b>	<p>The Committee considered an agenda which included the following:</p> <ul style="list-style-type: none"> <li>• Integrated Performance Report Month 09</li> <li>• Month 09 Finance Report</li> <li>• Performance Highlights including Recovery and Urgent and Emergency Care</li> <li>• Network Business Case</li> <li>• Contract award recommendation – Data Network upgrade</li> <li>• Bed Replacement Business Case</li> <li>• 2022/23 Financial Planning</li> <li>• Workforce Update</li> <li>• Extension of Mobile CT contract</li> <li>• Extension of Mobile MRI contract</li> <li>• Update reports from sub-committee</li> </ul>
2a	<b>Alert</b>	<p>The Committee wish to alert members of the Board that:</p> <ul style="list-style-type: none"> <li>• Bed capacity and space remains a significant challenge with Medically-fit for Discharge (MFFD) running at circa 150/day with a length of stay of the MFFD patients of 5 days. This is a continuing regional and system-wide issue, with system partners focused on supporting all pathways.</li> <li>• The pressures have resulted in increased use of escalation capacity, delays in flow from Emergency Departments and extended ambulance handover delays at times.</li> <li>• The impact and unpredictability of absence levels was also of concern across both sites and this has also led to the short-notice cancellation of some theatre and outpatients sessions, including cancer cases.</li> <li>• Despite recruitment and temporary staff, the Trust has a 7% shortfall in WTE establishment which is further exacerbated by the monthly leavers rate (~65/month).</li> <li>• COVID remains a significant factor for Infection Prevention and Control, on patients and on staff. Telford &amp; Wrekin recorded the highest number of cases in the West Midlands recently, with Covid Inpatient levels steady since late December; the Trust is not able to forecast a significant reduction as yet.</li> <li>• The 104 weeks remains a very clear political target. The submitted trajectory as at 31 March is 74, and at present we have</li> </ul>

		<p>a few non-admitted patients (ie outpatient needed) and more needing surgery (see table below).</p> <ul style="list-style-type: none"> <li>• There is currently a £15-30m gap in the 22/23 financial plan.</li> </ul>		
2b	<b>Assurance</b>	<p>The Committee wish to assure members of the Board that:</p> <ul style="list-style-type: none"> <li>• Collaboration talks were taking place with Shropcom and RJAH regarding them joining the SaTH staffing roster solution, which may generate a cost saving.</li> <li>• International recruitment programme continues and is a key element of the people plan with a further 100 in the pipeline.</li> <li>• Education and benefits regarding the COVID-19 vaccination would continue to be reinforced regardless of the government regulation change.</li> <li>• Workforce establishment data was being validated and a more robust Workforce Operational Plan should be available by April 2022.</li> <li>• The 1.6% Efficiency CIP target looks likely to be achieved.</li> <li>• The work on the 2022/23 Financial Planning is well advanced and will be worked up ready for submission to the System in early March.</li> </ul>		
2c	<b>Advise</b>	<p>The Committee wish to advise members of the Board that:</p> <ul style="list-style-type: none"> <li>• A target of 4% sickness rate is outlined in the current People Strategy which will need to be refreshed given the operational circumstances.</li> <li>• The Trust was caring for circa 74 COVID-19 positive inpatients.</li> <li>• The Capital Programme has increased to circa £48.9m however the current expenditure forecast is only £44.6m due to two projected underspends.(Diagnostic Hub and Emergency PDC)</li> <li>• The Network Business Case was fully supported.</li> <li>• The Contract Award Recommendation for Data Network Upgrade was fully supported.</li> <li>• The Bed Replacement Business Case was fully supported and recommended for approval by the Board of Directors.</li> <li>• The extension of the Mobile CT contract was fully supported.</li> <li>• The extension of the Mobile MRI contract was fully supported.</li> </ul>		
3	<b>Actions to be considered by the Board</b>	<ul style="list-style-type: none"> <li>• Network Business case and Data Network upgrade</li> <li>• Bed Replacement Business case</li> <li>• Contract Extensions for CT and MRI</li> </ul>		
4	<b>Report compiled by</b>	<i>Clive Deadman Chair</i>	<b>Minutes available from</b>	<i>Jo Wells Committee Support</i>

Specialty	Total 31.1.22. over 104 weeks	Cohort to 31.3.22	not booked	Year End Plan
OPHTHALMOLOGY	9	43	12	19
TRAUMA & ORTHOPAEDICS	18	31	29	10
UPPER GASTROINTESTINAL SURGERY	9	19	6	12
GYNAECOLOGY	2	4	2	7
VASCULAR SURGERY	8	15	10	5
UROLOGY	1	2	0	2
COLORECTAL SURGERY	5	7	5	8
ENT	0	1	1	6
MAXILLO FACIAL SURGERY	1			1
CARDIOLOGY	0			
PAIN MANAGEMENT	7	14	14	
BREAST SURGERY	0	1	1	
Other	1	7	3	4
<b>Total 104 week breaches</b>	<b>61</b>	<b>144</b>	<b>83</b>	<b>74</b>